Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGM120 + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- NGM Biopharmaceuticals
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous (NGM120)
01
Overview
NGM120 + gemcitabine + nab-paclitaxel is a combination regimen under investigation primarily for the treatment of metastatic pancreatic cancer. **NGM120** is a novel, antagonistic monoclonal antibody targeting **glial cell-derived neurotrophic factor receptor alpha-like (GFRAL)**, thereby inhibiting **growth differentiation factor 15 (GDF15)** signaling, which plays a key role in cancer-associated cachexia and tumor progression. **Gemcitabine** is a nucleoside analog chemotherapeutic agent inhibiting DNA synthesis, and **nab-paclitaxel** is paclitaxel bound to albumin nanoparticles, facilitating delivery to tumor cells and disrupting microtubule dynamics to inhibit cell division. The combination regimen aims to enhance antitumor efficacy and control cancer-induced wasting.
- Brand names
- Abraxane
- Other names
- nab-paclitaxelgemcitabineNGM120NGM-120NGM 120
02
Targets
TUBB (Tubulin (alpha and beta subunits))RNR (Ribonucleotide reductase)DNA polymerase familyGFRAL (Glial-derived neurotrophic factor family receptor alpha-like/ret receptor complex)
Beyond the preview
Go deeper on NGM120 + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGM120 + gemcitabine + nab-paclitaxel.